181 related articles for article (PubMed ID: 1579408)
1. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group.
Steinherz LJ; Graham T; Hurwitz R; Sondheimer HM; Schwartz RG; Shaffer EM; Sandor G; Benson L; Williams R
Pediatrics; 1992 May; 89(5 Pt 1):942-9. PubMed ID: 1579408
[TBL] [Abstract][Full Text] [Related]
2. Monitoring for anthracycline cardiotoxicity.
Lipshultz SE; Sanders SP; Goorin AM; Krischer JP; Sallan SE; Colan SD
Pediatrics; 1994 Mar; 93(3):433-7. PubMed ID: 7818624
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of anthracycline-induced cardiotoxicity.
Jannazzo A; Hoffman J; Lutz M
Ann Pharmacother; 2008 Jan; 42(1):99-104. PubMed ID: 18094345
[TBL] [Abstract][Full Text] [Related]
4. Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials.
van Dalen EC; van den Brug M; Caron HN; Kremer LC
Eur J Cancer; 2006 Dec; 42(18):3199-205. PubMed ID: 17011186
[TBL] [Abstract][Full Text] [Related]
5. Reducing the cardiotoxicity of the anthracyclines.
Carlson RW
Oncology (Williston Park); 1992 Jun; 6(6):95-100, 104, 107, discussion 107-8. PubMed ID: 1535212
[TBL] [Abstract][Full Text] [Related]
6. [Anthracycline-induced cardiotoxicity: monitoring and prevention of the lesion].
Orditura M; De Vita F; Ciaramella F; Catalano G
Ann Ital Med Int; 1994; 9(4):243-8. PubMed ID: 7893575
[TBL] [Abstract][Full Text] [Related]
7. Clinical and non-invasive assessment of anthracycline cardiotoxicity: perspectives on myocardial protection.
Mortensen SA; Aabo K; Jonsson T; Baandrup U
Int J Clin Pharmacol Res; 1986; 6(2):137-50. PubMed ID: 3459718
[TBL] [Abstract][Full Text] [Related]
8. Anthracycline cardiotoxicity in long-term survivors of childhood cancer.
Scully RE; Lipshultz SE
Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816
[TBL] [Abstract][Full Text] [Related]
9. Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity.
Yaris N; Ceviz N; Coskun T; Akytüz C; Büyükpamukçu M
J Exp Clin Cancer Res; 2002 Jun; 21(2):165-70. PubMed ID: 12148572
[TBL] [Abstract][Full Text] [Related]
10. Cardiac functions by myocardial performance index and QT dispersion in survivors of childhood lymphoblastic leukaemia.
Gulen H; Kazanci E; Mese T; Uzunkaya D; Erbay A; Tavli V; Vergin C
Minerva Pediatr; 2007 Apr; 59(2):107-13. PubMed ID: 17404560
[TBL] [Abstract][Full Text] [Related]
11. Multicentre analysis of anthracycline-induced cardiotoxicity in children following treatment according to the nephroblastoma studies SIOP No.9/GPOH and SIOP 93-01/GPOH.
Marx M; Langer T; Graf N; Hausdorf G; Stöhr W; Ludwig R; Beck JD
Med Pediatr Oncol; 2002 Jul; 39(1):18-24. PubMed ID: 12116074
[TBL] [Abstract][Full Text] [Related]
12. [Cardiotoxicity of anthracyclines].
Ferrière M; Donadio D; Ramirez R
Arch Mal Coeur Vaiss; 1993 Feb; 86 Spec No 2():53-8. PubMed ID: 8215791
[TBL] [Abstract][Full Text] [Related]
13. [Cardiologic sequelae of cytostatic therapy].
Mladosievivcová B
Cas Lek Cesk; 2001 Mar; 140(5):138-41. PubMed ID: 11347200
[TBL] [Abstract][Full Text] [Related]
14. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy.
Pinarli FG; Oğuz A; Tunaoğlu FS; Karadeniz C; Gökçora N; Elbeg S
Pediatr Blood Cancer; 2005 Apr; 44(4):370-7. PubMed ID: 15602715
[TBL] [Abstract][Full Text] [Related]
15. Overview of cardiac pathology in relation to anthracycline cardiotoxicity.
Ferrans VJ
Cancer Treat Rep; 1978 Jun; 62(6):955-61. PubMed ID: 352510
[TBL] [Abstract][Full Text] [Related]
16. Systolic time intervals in monitoring for anthracycline cardiomyopathy in pediatric patients.
Hutchinson RJ; Bailey C; Wood D; Donaldson MH
Cancer Treat Rep; 1978 Jun; 62(6):907-10. PubMed ID: 667866
[TBL] [Abstract][Full Text] [Related]
17. The evaluation of left ventricular function in childhood cancer survivors by pharmacological stress echocardiography.
Elbl L; Hrstkova H; Chaloupka V; Novotny J; Michalek J
Neoplasma; 2003; 50(3):191-7. PubMed ID: 12937852
[TBL] [Abstract][Full Text] [Related]
18. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors.
Robert J
Cardiovasc Toxicol; 2007; 7(2):135-9. PubMed ID: 17652818
[TBL] [Abstract][Full Text] [Related]
19. [Cardiotoxicity of anthracycline cytostatic agents--a proposal for routine monitoring and supportive therapy].
Svojgrová M; Slechtová J; Hůla J
Vnitr Lek; 1991 Feb; 37(2):151-9. PubMed ID: 2021075
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of the cardiac toxicity of 4'-deoxy-doxorubicin.
Villani F; Galimberti M; Comazzi R; Crippa F; Bonfante V; Ferrari L; Pacciarini MA
Int J Clin Pharmacol Ther Toxicol; 1988 Apr; 26(4):185-9. PubMed ID: 3403095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
